Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News   The Market Herald News   Sona Nanotech (CSE:SONA) secures Bentley...

Sona Nanotech (CSE:SONA) secures Bentley Biomedical

Brieanna McCutcheon , The Market Online
0 Comments| April 13, 2023
{{labelSign}}  Favorites
{{errorMessage}}
    • Sona Nanotech (SONA) secures Bentley Biomedical for its THT Colorectal Cancer Therapy Development
    • President and Principal Consultant, Shepard Bentley will act as lead consultant to Sona
    • Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles
    • Bentley Biomedical will be responsible for regulatory strategies leading towards FDA approval
    • Sona Nanotech stock (CSE:SONA) is down 3.12 per cent, trading at C$0.16 at 2:42 pm EST
  • Sona Nanotech (SONA) is enlisting the help of Bentley Biomedical Consulting for its pre-clinical and clinical study preparations.
  • Through this, the President and Principal Consultant, Shepard Bentley will act as lead consultant to Sona.
  • Bentley Biomedical will be responsible for regulatory strategies leading towards FDA approval.
  • Bentley was also a founder of Volcano Therapeutics, Inc. which was acquired by Philips and is a member of the American Society for Quality – Biomedical Section, the Association for Advancement of Medical Instrumentation, and the Regulatory Affairs Professional Society.
  • When asked about the new work ahead, Bentley was positive about the outcome. “I look forward to working with THT developer Len Pagliaro to take it to the next level as the Company develops pre-clinical studies as it prepares to submit for an IDE and eventual clinical trials for this innovative therapy.”
  • David Regan, CEO of Sona also added his thoughts on the news, “Bentley Biomedical is one of the few regulatory consultants with direct experience achieving regulatory approvals for systems involving both nanoparticles and photothermal therapy.”
  • Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles.
  • Siva Therapeutics Inc is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors.
  • The heat is delivered to tumors by infrared light that is absorbed by SivaRods™ gold nanorods in the tumor and re-emitted as heat.
  • Sona Nanotech (SONA) is down 3.12 per cent, trading at C$0.16 at 2:42 pm EST.


{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company

Strategic Resources Inc.

Strategic Resources Inc.

Strategic Resources is a Canada based development company focused on vanadium, high purity iron ...
View More »